Literature DB >> 1382325

Neutralization of myotoxic phospholipases A2 from the venom of the snake Bothrops asper by monoclonal antibodies.

B Lomonte1, J M Gutiérrez, M Ramírez, C Díaz.   

Abstract

The neutralization of two myotoxic phospholipases A2 from the venom of Bothrops asper, myotoxins I and II, by two murine monoclonal antibodies is reported. The monoclonal antibodies, MAb-3 and Mab-4, recognize different epitopes of the toxin. Both antibodies completely neutralized myotoxic activity of myotoxin I and crude venom. MAb-3 also completely neutralized myotoxic activity of myotoxin II, a lysine-49 phospholipase A2 isoform, whereas MAb-4 neutralized this toxin only partially. MAb-3 neutralized myotoxin II at a molar ratio of 1:1, showing a higher efficiency than affinity-purified polyclonal antibodies. A dissociation of myotoxic and enzymatic activities of myotoxin I was observed with both monoclonal antibodies.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1382325     DOI： 10.1016/0041-0101(92)90866-4

Source DB:  PubMed          Journal:  Toxicon        ISSN： 0041-0101            Impact factor:   3.033


  7 in total

1.  Structural and functional studies of a bothropic myotoxin complexed to rosmarinic acid: new insights into Lys49-PLA₂ inhibition.

Authors:  Juliana I Dos Santos; Fábio F Cardoso; Andreimar M Soares; Maeli Dal Pai Silva; Márcia Gallacci; Marcos R M Fontes
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

Review 2.  Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Authors:  Larissa M Alvarenga; Muhammad Zahid; Anne di Tommaso; Matthieu O Juste; Nicolas Aubrey; Philippe Billiald; Julien Muzard
Journal:  Toxins (Basel)       Date:  2014-08-21       Impact factor: 4.546

3.  Isolation and structural characterization of bioactive compound from Aristolochia sprucei aqueous extract with anti-myotoxic activity.

Authors:  Isela I González Rodríguez; Aleff F Francisco; Leandro S Moreira-Dill; Aristides Quintero; César L S Guimarães; Carlos A H Fernandes; Agnes A S Takeda; Fernando B Zanchi; Cléopatra A S Caldeira; Paulo S Pereira; Marcos R M Fontes; Juliana P Zuliani; Andreimar M Soares
Journal:  Toxicon X       Date:  2020-06-20

4.  Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.

Authors:  Andreas Hougaard Laustsen; Netty Dorrestijn
Journal:  Toxins (Basel)       Date:  2018-07-31       Impact factor: 4.546

5.  Comparative characterization of Viperidae snake venoms from Perú reveals two compositional patterns of phospholipase A2 expression.

Authors:  Bruno Lomonte; Cecilia Díaz; Fernando Chaves; Julián Fernández; Marco Ruiz; María Salas; Alfonso Zavaleta; Juan J Calvete; Mahmood Sasa
Journal:  Toxicon X       Date:  2020-05-30

6.  Biochemical characterization and pharmacological properties of new basic PLA2 BrTX-I isolated from Bothrops roedingeri (Roedinger's Lancehead) Mertens, 1942, snake venom.

Authors:  Mauricio Aurelio Gomes Heleno; Paulo Aparecido Baldasso; Luis Alberto Ponce-Soto; Sérgio Marangoni
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

7.  Inhibition of the Myotoxicity Induced by Bothrops jararacussu Venom and Isolated Phospholipases A2 by Specific Camelid Single-Domain Antibody Fragments.

Authors:  Nidiane D R Prado; Soraya S Pereira; Michele P da Silva; Michelle S S Morais; Anderson M Kayano; Leandro S Moreira-Dill; Marcos B Luiz; Fernando B Zanchi; André L Fuly; Maribel E F Huacca; Cleberson F Fernandes; Leonardo A Calderon; Juliana P Zuliani; Luiz H Pereira da Silva; Andreimar M Soares; Rodrigo G Stabeli; Carla F C Fernandes
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.